Selected research
Industry Research
Exosome CDMO Industry Research Report 2026
Market perspective
The global Exosome CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Exosome CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Exosome CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Exosome CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Exosome CDMO include REPROCELL, Histocell, Lonza, MYCENAX, RoosterBio, Altaris LLC, Asahi Glass Co., Fortis Life Sciences and Scorpius BioManufacturing, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Exosome CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Exosome CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Exosome CDMO Market by Company
REPROCELL
Histocell
Lonza
MYCENAX
RoosterBio
Altaris LLC
Asahi Glass Co.
Fortis Life Sciences
Scorpius BioManufacturing
Miltenyi Bioindustry
Exothera
EXO Biologics
Porton Advanced
Elise Biopharma
Evox Therapeutics
FUJIFILM Biotechnologies
Exosome CDMO Segment by Type
Preclinical CRO
Clinical CRO
Exosome CDMO Segment by Application
Laboratory
Universities
Bio Industry
Medical Industry
Exosome CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Exosome CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Exosome CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Exosome CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Exosome CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Preclinical CRO
- Clinical CRO
Applications
- Laboratory
- Universities
- Bio Industry
- Medical Industry
Companies covered
- REPROCELL
- Histocell
- Lonza
- MYCENAX
- RoosterBio
- Altaris LLC
- Asahi Glass Co.
- Fortis Life Sciences
- Scorpius BioManufacturing
- Miltenyi Bioindustry
- Exothera
- EXO Biologics
- Porton Advanced
- Elise Biopharma
- Evox Therapeutics
- FUJIFILM Biotechnologies
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Exosome CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Preclinical CRO
- 2.2.3 Clinical CRO
- 2.3 Exosome CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Laboratory
- 2.3.3 Universities
- 2.3.4 Bio Industry
- 2.3.5 Medical Industry
- 2.4 Assumptions and Limitations
3 Exosome CDMO Breakdown Data by Type
- 3.1 Global Exosome CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Exosome CDMO Forecasted Market Size by Type (2027-2032)
4 Exosome CDMO Breakdown Data by Application
- 4.1 Global Exosome CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Exosome CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Exosome CDMO Market Perspective (2021-2032)
- 5.2 Global Exosome CDMO Growth Trends by Region
- 5.2.1 Global Exosome CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Exosome CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Exosome CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Exosome CDMO Market Dynamics
- 5.3.1 Exosome CDMO Industry Trends
- 5.3.2 Exosome CDMO Market Drivers
- 5.3.3 Exosome CDMO Market Challenges
- 5.3.4 Exosome CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Exosome CDMO Players by Revenue
- 6.1.1 Global Top Exosome CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Exosome CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Exosome CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Exosome CDMO Head Office and Area Served
- 6.4 Global Exosome CDMO Players, Product Type & Application
- 6.5 Global Exosome CDMO Manufacturers Established Date
- 6.6 Global Exosome CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Exosome CDMO Market Size (2021-2032)
- 7.2 North America Exosome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Exosome CDMO Market Size by Country (2021-2026)
- 7.4 North America Exosome CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Exosome CDMO Market Size (2021-2032)
- 8.2 Europe Exosome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Exosome CDMO Market Size by Country (2021-2026)
- 8.4 Europe Exosome CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Exosome CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Exosome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Exosome CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Exosome CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Exosome CDMO Market Size (2021-2032)
- 10.2 South America Exosome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Exosome CDMO Market Size by Country (2021-2026)
- 10.4 South America Exosome CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Exosome CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Exosome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Exosome CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Exosome CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 REPROCELL
- 12.1.1 REPROCELL Company Information
- 12.1.2 REPROCELL Business Overview
- 12.1.3 REPROCELL Revenue in Exosome CDMO Business (2021-2026)
- 12.1.4 REPROCELL Exosome CDMO Product Portfolio
- 12.1.5 REPROCELL Recent Developments
- 12.2 Histocell
- 12.2.1 Histocell Company Information
- 12.2.2 Histocell Business Overview
- 12.2.3 Histocell Revenue in Exosome CDMO Business (2021-2026)
- 12.2.4 Histocell Exosome CDMO Product Portfolio
- 12.2.5 Histocell Recent Developments
- 12.3 Lonza
- 12.3.1 Lonza Company Information
- 12.3.2 Lonza Business Overview
- 12.3.3 Lonza Revenue in Exosome CDMO Business (2021-2026)
- 12.3.4 Lonza Exosome CDMO Product Portfolio
- 12.3.5 Lonza Recent Developments
- 12.4 MYCENAX
- 12.4.1 MYCENAX Company Information
- 12.4.2 MYCENAX Business Overview
- 12.4.3 MYCENAX Revenue in Exosome CDMO Business (2021-2026)
- 12.4.4 MYCENAX Exosome CDMO Product Portfolio
- 12.4.5 MYCENAX Recent Developments
- 12.5 RoosterBio
- 12.5.1 RoosterBio Company Information
- 12.5.2 RoosterBio Business Overview
- 12.5.3 RoosterBio Revenue in Exosome CDMO Business (2021-2026)
- 12.5.4 RoosterBio Exosome CDMO Product Portfolio
- 12.5.5 RoosterBio Recent Developments
- 12.6 Altaris LLC
- 12.6.1 Altaris LLC Company Information
- 12.6.2 Altaris LLC Business Overview
- 12.6.3 Altaris LLC Revenue in Exosome CDMO Business (2021-2026)
- 12.6.4 Altaris LLC Exosome CDMO Product Portfolio
- 12.6.5 Altaris LLC Recent Developments
- 12.7 Asahi Glass Co.
- 12.7.1 Asahi Glass Co. Company Information
- 12.7.2 Asahi Glass Co. Business Overview
- 12.7.3 Asahi Glass Co. Revenue in Exosome CDMO Business (2021-2026)
- 12.7.4 Asahi Glass Co. Exosome CDMO Product Portfolio
- 12.7.5 Asahi Glass Co. Recent Developments
- 12.8 Fortis Life Sciences
- 12.8.1 Fortis Life Sciences Company Information
- 12.8.2 Fortis Life Sciences Business Overview
- 12.8.3 Fortis Life Sciences Revenue in Exosome CDMO Business (2021-2026)
- 12.8.4 Fortis Life Sciences Exosome CDMO Product Portfolio
- 12.8.5 Fortis Life Sciences Recent Developments
- 12.9 Scorpius BioManufacturing
- 12.9.1 Scorpius BioManufacturing Company Information
- 12.9.2 Scorpius BioManufacturing Business Overview
- 12.9.3 Scorpius BioManufacturing Revenue in Exosome CDMO Business (2021-2026)
- 12.9.4 Scorpius BioManufacturing Exosome CDMO Product Portfolio
- 12.9.5 Scorpius BioManufacturing Recent Developments
- 12.10 Miltenyi Bioindustry
- 12.10.1 Miltenyi Bioindustry Company Information
- 12.10.2 Miltenyi Bioindustry Business Overview
- 12.10.3 Miltenyi Bioindustry Revenue in Exosome CDMO Business (2021-2026)
- 12.10.4 Miltenyi Bioindustry Exosome CDMO Product Portfolio
- 12.10.5 Miltenyi Bioindustry Recent Developments
- 12.11 Exothera
- 12.11.1 Exothera Company Information
- 12.11.2 Exothera Business Overview
- 12.11.3 Exothera Revenue in Exosome CDMO Business (2021-2026)
- 12.11.4 Exothera Exosome CDMO Product Portfolio
- 12.11.5 Exothera Recent Developments
- 12.12 EXO Biologics
- 12.12.1 EXO Biologics Company Information
- 12.12.2 EXO Biologics Business Overview
- 12.12.3 EXO Biologics Revenue in Exosome CDMO Business (2021-2026)
- 12.12.4 EXO Biologics Exosome CDMO Product Portfolio
- 12.12.5 EXO Biologics Recent Developments
- 12.13 Porton Advanced
- 12.13.1 Porton Advanced Company Information
- 12.13.2 Porton Advanced Business Overview
- 12.13.3 Porton Advanced Revenue in Exosome CDMO Business (2021-2026)
- 12.13.4 Porton Advanced Exosome CDMO Product Portfolio
- 12.13.5 Porton Advanced Recent Developments
- 12.14 Elise Biopharma
- 12.14.1 Elise Biopharma Company Information
- 12.14.2 Elise Biopharma Business Overview
- 12.14.3 Elise Biopharma Revenue in Exosome CDMO Business (2021-2026)
- 12.14.4 Elise Biopharma Exosome CDMO Product Portfolio
- 12.14.5 Elise Biopharma Recent Developments
- 12.15 Evox Therapeutics
- 12.15.1 Evox Therapeutics Company Information
- 12.15.2 Evox Therapeutics Business Overview
- 12.15.3 Evox Therapeutics Revenue in Exosome CDMO Business (2021-2026)
- 12.15.4 Evox Therapeutics Exosome CDMO Product Portfolio
- 12.15.5 Evox Therapeutics Recent Developments
- 12.16 FUJIFILM Biotechnologies
- 12.16.1 FUJIFILM Biotechnologies Company Information
- 12.16.2 FUJIFILM Biotechnologies Business Overview
- 12.16.3 FUJIFILM Biotechnologies Revenue in Exosome CDMO Business (2021-2026)
- 12.16.4 FUJIFILM Biotechnologies Exosome CDMO Product Portfolio
- 12.16.5 FUJIFILM Biotechnologies Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst